PHI with Autoimmune thyroid disease type 1a
How does this condition affect your private health insurance?
Autoimmunthyreopathie Typ 1a, commonly known as Graves' disease, is an autoimmune disorder where the body's immune system mistakenly attacks the thyroid gland. This causes the thyroid to become overactive (hyperthyroidism) and produce too much thyroid hormone. Symptoms include weight loss despite increased appetite, rapid or irregular heartbeat, tremors, anxiety, heat intolerance, and fatigue. A distinguishing feature in some cases is Graves' ophthalmopathy, affecting the eyes. Untreated hyperthyroidism can lead to severe cardiovascular complications and a life-threatening condition called thyroid storm. Diagnosis involves blood tests measuring thyroid hormones and antibodies. Treatment options include antithyroid medications, radioactive iodine therapy, or surgery to manage hormone levels and symptoms.
PKV Risk Assessment
However, some specialized PHI providers may insure you with a surcharge of up to 20%.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Symptoms develop over weeks to months; initial treatment phase typically lasts 12-18 months with medication.
Duration of Illness (Lifetime)
Often chronic, characterized by periods of remission and relapse, requiring lifelong monitoring and potential ongoing treatment.
Cost of Treatment (Initial)
Moderate to high, typically ranging from hundreds to several thousands of USD/EUR for initial diagnosis and medication regimen.
Cost of Treatment (Lifetime)
High, potentially tens of thousands of USD/EUR over a lifetime, depending on the need for radioactive iodine, surgery, and chronic management of complications.
Mortality Rate
Low with appropriate treatment, but significantly increased if untreated, particularly due to thyroid storm or severe cardiovascular complications.
Risk of Secondary Damages
Moderate to high (25-50% for Graves' ophthalmopathy, increased risk of cardiovascular issues, osteoporosis, and psychological impact).
Probability of Full Recovery
Moderate. Remission rates after antithyroid drug therapy are around 30-50%, but recurrence is common. Lifelong monitoring is often necessary.
Underlying Disease Risk
Moderate to high. There is an increased likelihood of co-occurring autoimmune conditions such as Type 1 diabetes, pernicious anemia, vitiligo, and rheumatoid arthritis (up to 20-30% of patients).